Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies

2909 - Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from Arm A of the Phase II BALTIC study


21 Oct 2018


Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies



Tumour Site


Igor Bondarenko


Annals of Oncology (2018) 29 (suppl_8): viii596-viii602. 10.1093/annonc/mdy298


I. Bondarenko1, O. Juan-Vidal2, G. Pajkos3, A. Kryzhanivska4, Z. Pápai Székely5, D. Vicente6, I.O. Vynnychenko7, S. Jones8, Y. Wang8, H. Jiang8, N. Reinmuth9

Author affiliations

  • 1 Oncology, Dnipropetrovsk State Medical Academy, 49000 - Dnipropetrovsk/UA
  • 2 Medical Oncology, La Fe University Hospital, Valencia/ES
  • 3 Medical Oncology, Bacs-Kiskun County Hospital, Kecskemét/HU
  • 4 Department Of Oncology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk/UA
  • 5 Medical Oncology, St George Hospital of Fejér County, Szekesfehervar/HU
  • 6 Medical Oncology, Hospital Universitario Virgen Macarena, Seville/ES
  • 7 Medical Oncology, Sumy State University, 40005 - Sumy/UA
  • 8 Medical Oncology, AstraZeneca, Gaithersburg/US
  • 9 Medical Oncology, Asklepios Lung Clinic, Munich-Gauting/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2909


Prognosis in extensive-stage disease small cell lung cancer (ED-SCLC) is poor and patients (pts) commonly relapse within months of completing first-line platinum-based chemotherapy (CT). Investigation into a potential role for immune checkpoint inhibitors in SCLC treatment is supported by good scientific rationale, principally the high mutational burden associated with the disease. We report preliminary efficacy of anti-PD-L1 mAb durvalumab (D) plus anti-CTL4 mAb tremelimumab (T) in pts with platinum-refractory/resistant ED-SCLC, as assessed in Arm A of BALTIC (NCT02937818), a Phase II, multi-arm, signal-searching study.


Eligible pts had ED-SCLC, disease progression (PD) during or within 90 days of completing first-line platinum-based CT, WHO/ECOG performance status 0 or 1, and a life expectancy ≥8 weeks. Pts enrolled in Arm A received D 1500 mg + T 75 mg IV q4w for up to 4 months, followed by D 1500 mg IV q4w monotherapy from Week 16 until PD or discontinuation. The primary endpoint was objective response rate (ORR; investigator assessment, RECIST v1.1). Secondary endpoints included disease control rate (DCR), progression free survival (PFS), overall survival (OS), and safety and tolerability.


25 pts were enrolled between November 2016 and September 2017, and 21 pts received study treatment (mean age 59.6 years; 71.4% male). As of 02 Feb 2018 (data cut off), median duration of treatment was approximately 14 weeks, with D treatment ongoing in 3 pts and T treatment ongoing in 2 pts. ORR was 9.5% (2 pts; 95% CI 1.17, 30.38). Both were partial responses. 5 pts (23.8%) had stable disease and 1 pt (4.8%) had an unconfirmed partial response. DCR at 12 weeks was 8/21 (38.1%). Grade 3 or higher adverse events (AEs; all cause) occurred in 10 pts (48%), of which 4 pts (19%) experienced an event deemed possibly causally related to treatment by the investigator. 1 pt (4.8%) discontinued due to a possibly causally related AE. Updated ORR, DCR and safety data will be presented, as well as PFS and OS data.


D in combination with T demonstrated a tolerable safety profile and encouraging anti-tumour activity in pts with platinum-refractory/resistant ED-SCLC, a difficult-to-treat patient population.

Clinical trial identification

NCT02937818 (October 5, 2016).

Legal entity responsible for the study




Editorial Acknowledgement

Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Paul Glacken, MSc, and Elizabeth Andrew, PhD, of Cirrus Communications (Macclesfield, UK), an Ashfield company, and was funded by AstraZeneca.


S. Jones: Former employment: AstraZeneca; Consultant, equity owner: AstraZeneca. H. Jiang: Employment, equity ownership: AstraZeneca. N. Reinmuth: Personal fees: BMS, Roche, AstraZeneca, Takeda, Novartis, MSD, Lilly, Boehringer-Ingelheim outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.